Purchase this article with an account.
K. Hirooka, H. Yang, K. Fukuda, M. Mizote, F. Shiraga; Deleterious Role of Anti-High Mobility Group Box 1 Monoclonal Antibody in Retinal Ischemia-Reperfusion Injury. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4698.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the effect of anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) against ischemia reperfusion injury in the rat retina.
Retinal ischemia was induced by increasing intraocular pressure to 130 mmHg and maintaining that level for 45 minutes. An intraperitoneal injection of HMGB1 was administered 30 min before ischemia. At 7 days after the ischemia, retinal damage was evaluated. Immunohistochemistry and image analysis were used to measure changes in the levels of reactive oxygen species (ROS) and the localization of anti-HMGB1 mAb. Dark-adapted full-field electroretinography (ERG) was also performed.
Pretreatment with anti-HMGB1 mAb significantly enhanced the ischemic injury of the inner retina. Anti-HMGB1 mAb expression increased at 6 to 12 hours after ischemia in the inner retina. After the ischemia, production of ROS was detected in retinal cells. However, pretreatment with anti-HMGB1 mAb increased the production of ROS. On the seventh postoperative day, the amplitudes of the ERG b-waves were significantly higher in the vehicle group than in the groups pretreated with anti-HMGB1 mAb.
Anti-HMGB1 mAb plays a large deleterious role in ischemia-reperfusion injury in an in vivo model of retinal injury. Anti-HMGB1 mAb function should be further explored to develop neuroprotective therapeutic strategies for acute retinal ischemic disorders.
This PDF is available to Subscribers Only